The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Enhanced antibody half-life improves in vivo activity
Open accessAbstract
Improved affinity for the neonatal Fc receptor (FcRn) is known to extend antibody half-life in vivo. However, this has never been linked with enhanced therapeutic efficacy. We tested whether antibodies with half-lives extended up to fivefold in human (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing intervals. We observed that prolonged exposure due to FcRn-mediated enhancement of half-life improved antitumor activity of Fc-engineered antibodies in an hFcRn/Rag1−/− mouse model. This bridges the demand for dosing convenience with the clinical necessity of maintaining efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Self-citationPresta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 314
Self-citationFan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Lin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804182 · Cited by 237
Cited by
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Self-citationThe journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Strategies for extended serum half-life of protein therapeutics
Kontermann, R. E. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.012 · Cited by 573
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Progress in biopharmaceutical development
Kesik‐Brodacka, M. (2018) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 353
Igawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Kwong, P. D., Mascola, J. R., & Nabel, G. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3516 · Cited by 329
Polymeric microneedles for transdermal protein delivery
Ye, Y., Yu, J., Wen, D., Kahkoska, A. R., & Gu, Z. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.015 · Cited by 324
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Schäfer, A., Muecksch, F., Lorenzi, J. C. C., Leist, S. R., Cipolla, M., Bournazos, S., Schmidt, F., Maison, R. M., Gazumyan, A., Martinez, D. R., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201993 · Cited by 305
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Pyzik, M., Rath, T., Lencer, W. I., Baker, K., & Blumberg, R. S. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1403014 · Cited by 298
The therapeutic age of the neonatal Fc receptor
Pyzik, M., Kozicky, L. K., Gandhi, A. K., & Blumberg, R. S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00821-1 · Cited by 288
Rudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02213-14 · Cited by 282
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Monoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 269
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray
Walker, L. M., & Burton, D. R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.148 · Cited by 268
Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms
Oganesyan, V., Damschroder, M. M., Cook, K. E., Li, Q., Gao, C., Wu, H., & Dall'Acqua, W. F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.537563 · Cited by 259
Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., & Ionescu, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.009 · Cited by 257
Isotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
A strategy for risk mitigation of antibodies with fast clearance
Hötzel, I., Theil, F.-P., Bernstein, L. J., Prabhu, S., Deng, R., Quintana, L., Lutman, J., Sibia, R., Chan, P., Bumbaca, D., et al. (2012) · mAbs · doi:10.4161/mabs.22189 · Cited by 245
Kose, N., Fox, J. M., Sapparapu, G., Bombardi, R., Tennekoon, R. N., de Silva, A. D., Elbashir, S. M., Theisen, M. A., Humphris-Narayanan, E., Ciaramella, G., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw6647 · Cited by 202
Wada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor (FcRn) Binding
Andersen, J. T., Dalhus, B., Viuff, D., Ravn, B. T., Gunnarsen, K. S., Plumridge, A., Bunting, K., Antunes, F., Williamson, R., Athwal, S., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.549832 · Cited by 167
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
Grevys, A., Nilsen, J., Sand, K. M. K., Daba, M. B., Øynebråten, I., Bern, M., McAdam, M. B., Foss, S., Schlothauer, T., Michaelsen, T. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03061-x · Cited by 98
Self-citationDelidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 87
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
(2018) · doi:10.1080/19420862.2017.1389355 · Cited by 80
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78
“, 2000); GAALIE, G236A/A330L/I332E (Weit8L/N434S (Zalevsky et al., 2010); TM, triple mutant in Fc, L234F/L235E/P331S”
Human and Non-Human Primate Intestinal FcRn Expression and Immunoglobulin G Transcytosis
Hornby, P. J., Cooper, P. R., Kliwinski, C., Ragwan, E., Mabus, J. R., Harman, B., Thompson, S., Kauffman, A. L., Yan, Z., Tam, S. H., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-013-1212-3 · Cited by 78
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
Grevys, A., Frick, R., Mester, S., Flem-Karlsen, K., Nilsen, J., Foss, S., Sand, K. M. K., Emrich, T., Fischer, J. A. A., Greiff, V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103746 · Cited by 51
Haraya, K., Tachibana, T., & Nezu, J. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.05.002 · Cited by 43
Developing the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Czajkowsky, D. M., Andersen, J. T., Fuchs, A., Wilson, T. J., Mekhaiel, D., Colonna, M., He, J., Shao, Z., Mitchell, D. A., Wu, G., et al. (2015) · Scientific Reports · doi:10.1038/srep09526 · Cited by 38
Engineering humoral immunity as prophylaxis or therapy
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.06.014 · Cited by 27
Metadata
- Authors
- Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R.
- Venue
- Nature Biotechnology
- Published
- 2010-01-17
- Volume
- 28
- Issue
- 2
- Pages
- 157-159
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1979162895
- Cited by
- 653
- References
- 14
- FWCI
- 25.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.